Latest news
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 11:43:00 GMTCEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 12:00:00 GMTLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Business WireBusiness Wire · Thu, 30 Jul 2026 12:31:00 GMT